- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Therapeutic Concepts for Treatment of Patients with Non-infectious Uveitis Biologic Disease Modifying Antirheumatic Drugs (Pubmed Central) - Sep 8, 2019
...Currently, the TNF-α-inhibitor Adalimumab is the only in-label therapeutic option, whereas, all other bDMARDs need to be given as an off-label therapy...All bDMARDs need to be administered parenterally, and therapy is initiated by the treating internal specialist only after interdisciplinary coordination of all treating subspecialties and after exclusion of contraindications. Regular clinical and laboratory monitoring is mandatory for all patients while under bDMARD therapy.
- |||||||||| Stelara (ustekinumab) / J&J, Humira (adalimumab) / Eisai, AbbVie
Journal: Progressive renal insufficiency in a 55-year-old man with psoriasis (Pubmed Central) - Sep 8, 2019
However, little is known about renal complications and possible causality of renal injury due to this treatment. The following case of a patient with psoriasis demonstrates the difficulties in classifying renal complications of anti-TNF-α therapy versus kidney involvement caused by the underlying disease.
- |||||||||| Humira (adalimumab) / AbbVie
Enrollment open: ADVISE: Adalimumab vs. Conventional Immunosuppression for Uveitis Trial (clinicaltrials.gov) - Sep 5, 2019
P3, N=222, Recruiting,
HBV reactivation occurred in 4.6% of RA patients with resolved HBV during the treatment with bDMARDs and the absence of anti-HBs may be a risk factor for the reactivation of resolved HBV. Not yet recruiting --> Recruiting
- |||||||||| Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim, Humira SC (adalimumab/hyaluronidase) / AbbVie, Halozyme Therapeutics, Humira (adalimumab) / Eisai, AbbVie
Clinical, P3 data, Clinical Trial,Phase I, Clinical Trial,Phase II, Clinical Trial,Phase III, Journal: Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. (Pubmed Central) - Sep 5, 2019
P3
No additional safety concerns were identified for patients who switched from adalimumab to risankizumab. Treatment with risankizumab provides flexibility in the long-term treatment of psoriasis.
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Occurrence of Uveitis in Rheumatic Disease Patients on TNF Inhibitors (Moscone Center EPOSTER & VIDEO TERMINALS) - Sep 5, 2019 - Abstract #AAO2019AAO_2637;
In patients with Behçet disease (BD), the recurrence risk was 5.2 times higher in adalimumab than in infliximab (P = .025). Conclusion Types of TNF agents may affect the recurrence of uveitis in BD patients, while having no effect on occurrence of uveitis in AS patients.
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Trial completion date, Trial primary completion date: Stricture Definition and Treatment (STRIDENT) Drug Therapy Study (clinicaltrials.gov) - Sep 4, 2019
P4, N=78, Recruiting,
Conclusion Types of TNF agents may affect the recurrence of uveitis in BD patients, while having no effect on occurrence of uveitis in AS patients. Trial completion date: Sep 2019 --> Sep 2020 | Trial primary completion date: Jul 2019 --> Sep 2020
- |||||||||| Journal, HEOR: Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis. (Pubmed Central) - Sep 1, 2019
There were uncertainties surrounding the results, the key drivers of which being the utility values, effectiveness of conventional therapy, and relative efficacy of the active treatments. The treatment with tofacitinib and vedolizumab for moderate-to-severe UC is likely to be the most favorable cost-effective option in the high-income UK, and tofacitinib is the most cost-effective option in the middle-income China.
- |||||||||| Inflectra (infliximab biosimilar IV) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer, Humira (adalimumab) / Eisai, AbbVie
Journal: Routinely utilized in-house assays for infliximab, adalimumab and their anti-drug antibody levels. (Pubmed Central) - Sep 1, 2019
Accurate and precise in-house ELISAs, highly comparable with commercial ELISAs and RGAs, were developed and validated for routine analysis of samples of patients treated with IFX (Remicade® or Remsima™) or ADL providing substantial cost benefit. Complex dissociation identified samples with anti-IFX-IFX (3%) and anti-ADL-ADL (14%) complexes indicating the benefit of adding acid dissociation to therapeutic drug monitoring of IFX and ADL.
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Retrospective data, Journal: Dosage adjustments in patients with psoriasis on adalimumab: a retrospective chart review. (Pubmed Central) - Aug 30, 2019
Adalimumab is a well-established treatment for chronic plaque psoriasis. While many clinical trials have shown its efficacy, few studies have looked at deviations from labeled dosing in the real-world setting.1 The aim of this study was to determine the frequency of off-label dosing in patients with psoriasis on adalimumab and the reasons for these deviations.
- |||||||||| Retrospective data, Review, Journal: Network meta-analyses of systemic treatments for psoriasis: a critical appraisal. (Pubmed Central) - Aug 30, 2019
While many clinical trials have shown its efficacy, few studies have looked at deviations from labeled dosing in the real-world setting.1 The aim of this study was to determine the frequency of off-label dosing in patients with psoriasis on adalimumab and the reasons for these deviations. Patients, clinicians, and policy-makers can use the relative efficacy assessments of NMAs to inform decision-making with regards to clearing of psoriasis skin lesions at relevant time points and improvement in quality of life.
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Retrospective data, Review, Journal: Hidradenitis suppurativa: A systematic review and meta-analysis of therapeutic interventions. (Pubmed Central) - Aug 30, 2019
...Adalimumab, an anti-tumor necrosis factor antibody, was superior to placebo in reducing Sartorius score (standardized mean difference = -0.32, confidence interval [-0.46, -0.18], P < 0.0001) and pain (risk ratio = 1.42, confidence interval [1.07, 1.9], P = 0.02), when given weekly (not every other week)...Surgery (either by simple excision or complete local excision followed by skin graft) is the first choice for intractable disease presenting in the late stages. However, the evidence on most of these treatments is deficient and further randomized trials are needed to establish the most efficient therapies for hidradenitis suppurativa management.
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Canada's Study of Adherence Outcomes in Patients Receiving Adalimumab: 3-Year Results From the COMPANION Study. (Pubmed Central) - Aug 30, 2019
Dr Ricceri provided in his letter further long-term follow-up data (60 months) on the use of etanercept or adalimumab in 17 psoriatic patients affected by past HBV infection or chronic HCV infection. CCCs were associated with greater adherence and improved persistence in these patients receiving adalimumab therapy over a 3-year period for IMID.
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Journal: Study of the mechanism for increased protein expression via transcription potency reduction of the selection marker. (Pubmed Central) - Aug 30, 2019
We then decreased the expression of GS gene by engineering a specific region of its SV40E promoter in these expression cassettes. By comparing the expression of GS and GOI at transcription and translation level before and after the SV40E promoter was weakened, we found that lower GS expression due to weaker SV40E transcription correlated well with the higher expression of recombinant proteins, mainly by increasing the copy number of GS and GOI integration into host cell genome.
- |||||||||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / Eisai, AbbVie
Trial completion date, Trial primary completion date: Cytokines and Genes in Therapeutic Response in Crohn's Disease (clinicaltrials.gov) - Aug 29, 2019
P=N/A, N=185, Enrolling by invitation,
By comparing the expression of GS and GOI at transcription and translation level before and after the SV40E promoter was weakened, we found that lower GS expression due to weaker SV40E transcription correlated well with the higher expression of recombinant proteins, mainly by increasing the copy number of GS and GOI integration into host cell genome. Trial completion date: Oct 2020 --> Oct 2021 | Trial primary completion date: Oct 2019 --> Oct 2020
- |||||||||| Pneumotox metrics: Drugs, patterns, users and countries. Foreground and quiet zones (N104) - Aug 26, 2019 - Abstract #ERS2019ERS_1737;
580 of 620 possible patterns of iatrogenic involvement were accessed, mainly several ILD subtypes, pleural effusion and pulmonary edema This body of data enables monitoring of commonly/uncommonly accessed and possibly ignored issues in iatrogenic respiratory disease in terms of both drugs and patterns, pointing to more comprehensive information or research needs in those areas. Silent zones in the world may help such Societies as the ERS address, shape and combat health inequities in iatrogenic disease and/or in other conditions
- |||||||||| Journal: S3 Guideline for the treatment of psoriasis vulgaris, update - Short version part 1 - Systemic treatment. (Pubmed Central) - Aug 25, 2019
The first section of this short version of the guideline covers systemic treatment options considered relevant by the expert panel and approved in Germany at the time of the consensus conference (acitretin, adalimumab, apremilast, cyclosporine, etanercept, fumaric acid esters, infliximab, methotrexate, secukinumab and ustekinumab). Detailed information is provided on the management and monitoring of the included treatment options.
- |||||||||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Higher body mass index and anti-drug antibodies predict the discontinuation of anti-TNF agents in Korean patients with axial spondyloarthritis. (Pubmed Central) - Aug 23, 2019
The incidence of tuberculosis was higher among users of synthetic DMARDs and anti-TNF than among users of synthetic DMARDs and synthetic DMARDs and non-anti-TNF biologics and also occurred later, suggesting infection during treatment and no screening failure. Our result suggests that the presence of anti-drug antibodies against adalimumab and infliximab as well as a higher body mass index can predict subsequent drug discontinuation in axial spondyloarthritis patients.
- |||||||||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Enbrel (etanercept) / Takeda, Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Latent tuberculosis infection screening in juvenile idiopathic arthritis patients preceding anti-TNF therapy in a tuberculosis high-risk country. (Pubmed Central) - Aug 23, 2019
Our result suggests that the presence of anti-drug antibodies against adalimumab and infliximab as well as a higher body mass index can predict subsequent drug discontinuation in axial spondyloarthritis patients. Long-term evaluation revealed that LTBI screening and primary prophylaxis before anti-TNF treatment was effective in a high-risk country and TST was the most sensitive parameter to identify these patients.
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Post-streptococcal uveitis syndrome in a Caucasian population: a case series. (Pubmed Central) - Aug 23, 2019
We also report on the benefit of adalimumab in the management of severe cases of PSUS; use of biologics in this particular cohort of uveitis patients has not previously been reported. With aggressive treatment our patients achieved good visual outcomes comparable to other published series.
- |||||||||| Retrospective data, Journal: Late-onset rheumatoid arthritis: clinical, biological, and therapeutic features About a retrospective study. (Pubmed Central) - Aug 22, 2019
Because of the co-morbidities, the clinician's perception of the patient's overall condition and the inaccuracies in the use of certain molecules in these patients, under-treatment may, on the contrary, weaken a patient whose remission will be postponed. This was not the case in our series, with a methodical use of methotrexate as well as effective dose biotherapies.
- |||||||||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Enbrel (etanercept) / Takeda, Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal, Real-World Evidence: Eight-year survival study of first-line tumour necrosis factor α inhibitors in rheumatoid arthritis: real-world data from a university centre registry. (Pubmed Central) - Aug 22, 2019
Infections and allergic reactions appear more often with infliximab, while serious infections did not differ among them. RA patients treated with infliximab are more likely to discontinue treatment earlier compared with the other alternatives.
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Trial completion date, Trial primary completion date: STRIVE: Juvenile Idiopathic Arthritis (JIA) Registry (clinicaltrials.gov) - Aug 21, 2019
P=N/A, N=849, Active, not recruiting,
Further study is needed to elucidate any potential beneficial effect of adalimumab on PSC. Trial completion date: Jun 2021 --> Feb 2024 | Trial primary completion date: Jun 2021 --> Feb 2024
- |||||||||| Retrospective data, Journal: Network meta-analysis of tofacitinib versus biologic treatments in moderate-to-severe rheumatoid arthritis patients. (Pubmed Central) - Aug 21, 2019
All biological DMARDs used in combination with methotrexate, except for etanercept, anakinra, certolizumab and tocilizumab without methotrexate, were displayed ETA on using ACR50 at week 24 in patients naïve to biological DMARDs. Etanercept displayed a greater difference in responses, although the high uncertainty of the comparative results prevented the confirmation of the increased efficacy of this drug.
|
